Research graph
References from Dynamic white blood cell kinetics enable early risk stratification of differentiation syndrome in low- and intermediate-risk acute promyelocytic leukemia. Local targets link to admitted publications; unresolved targets remain external evidence.
Differentiation syndrome in acute leukemia: Apl and beyond
10.3390/cancers15194767 · 2023 · External reference
Differentiation therapy for acute promyelocytic leukemia
10.1056/nejm199710093371509 · 1997 · External reference
Acute promyelocytic leukemia: Long-term outcomes from the Harmony Project
10.1182/blood.2024026186 · 2025 · External reference
Acute promyelocytic leukemia: Progress far and wide
10.1182/blood-2012-12-470757 · 2013 · External reference
Early mortality in patients with acute promyelocytic leukemia: A systematic review and meta-analysis
10.1186/s13054-025-05743-7 · 2025 · External reference
Characteristics and predictors of early hospital deaths in newly diagnosed Apl: A 13-year population-wide study
10.1182/bloodadvances.2021004789 · 2021 · External reference
Distinctive features associated with differentiation syndrome in acute promyelocytic leukemia in patients treated by all-trans retinoic acid and arsenic trioxide
10.1016/j.leukres.2024.107567 · 2024 · External reference
Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European Apl Group
10.1182/blood.v92.8.2712 · 1998 · External reference
Differentiation syndrome in acute promyelocytic leukaemia
10.1111/bjh.16151 · 2019 · External reference
Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide
10.1200/jco.2000.18.13.2620 · 2000 · External reference
Advances in understanding the pulmonary infiltration in acute promyelocytic leukaemia
10.1111/j.1365-2141.2010.08325.x · 2010 · External reference
Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: Triggering the differentiation syndrome
10.1182/blood-2009-02-204834 · 2009 · External reference
The "retinoic acid syndrome" in acute promyelocytic leukemia
10.7326/0003-4819-117-4-292 · 1992 · External reference
Progressive hyperleukocytosis is a relevant predictive marker for differentiation syndrome, early death, and subsequent relapse in acute promyelocytic leukemia
10.1038/s41598-019-47937-4 · 2019 · External reference
Dynamic changes and multiplication rate of white blood cell count may direct the timing of cytoreduction chemotherapy during induction treatment in newly diagnosed acute promyelocytic leukemia with low-intermediate risk
10.3892/mco.2021.2274 · 2021 · External reference
The kinetics of white blood cell and the predictive factors of leukocytosis under oral or intravenous arsenic as the first-line treatment for acute promyelocytic leukemia
10.1016/j.leukres.2017.09.006 · 2017 · External reference
Increased Bmi correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the Aida protocols
10.1182/blood-2011-07-369595 · 2012 · External reference
Influence of body mass index on incidence and prognosis of acute myeloid leukemia and acute promyelocytic leukemia: A meta-analysis
10.1038/s41598-017-18278-x · 2017 · External reference
Efficacy and safety analysis of different treatment regimens in newly diagnosed acute promyelocytic leukemia
10.1007/s00277-025-06495-8 · 2025 · External reference
Leucocytosis during induction therapy with all-trans-retinoic acid and arsenic trioxide in acute promyelocytic leukaemia predicts differentiation syndrome and treatment-related complications
10.1111/bjh.19759 · 2024 · External reference
Early predictor for differentiation syndrome in newly diagnosed acute promyelocytic leukaemia patients treated with single-agent arsenic trioxide
10.1007/s00277-024-05776-y · 2024 · External reference
Anti-inflammatory 25(Oh)D(3), a natural steroid hormone, may complement all-trans retinoic acid therapy for differentiation syndrome in acute promyelocytic leukemia
10.1038/s41419-025-08109-7 · 2025 · External reference
Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: A multicenter study by the Pethema Group
10.1182/blood-2003-07-2462 · 2004 · External reference
Management of acute promyelocytic leukemia: Updated recommendations from an expert panel of the European Leukemianet
10.1182/blood-2019-01-894980 · 2019 · External reference
Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: Characteristics, outcome, and prognostic factors
10.1182/blood-2008-07-168617 · 2009 · External reference
Improved prevention and treatment strategies for differentiation syndrome contribute to reducing early mortality in patients with acute promyelocytic leukemia
10.1038/s41408-024-01074-y · 2024 · External reference
Understanding the differentiation syndrome in acute promyelocytic leukemia: A comprehensive updated review
10.1007/s10637-025-01556-1 · 2025 · External reference
Does differentiation syndrome in newly diagnosed acute promyelocytic leukemia warrant systemic antifungal therapy? A real-world clinical study
10.1007/s00277-026-06729-3 · 2026 · External reference
Differentiation syndrome in acute myeloid leukemia: Molecular mechanisms, clinical spectrum, and emerging therapeutic paradigms
10.3390/ijms27041775 · 2026 · External reference
The expression of Slit2 and Robo1 increased during retinoic acid syndrome in acute promyelocytic leukemia and impacted differentiated cell migration
10.1016/j.tranon.2022.101370 · 2022 · External reference
Thromboembolism in adult patients with acute promyelocytic leukemia: Clinical characteristics, risk factors, and a predictive nomogram
10.1007/s00277-025-06251-y · 2025 · External reference
Predictors of early death, serious hemorrhage, and differentiation syndrome in Japanese patients with acute promyelocytic leukemia
10.1007/s00277-020-04245-6 · 2020 · External reference
Influence of white blood cell count trajectories on the risk of differentiation syndrome during induction therapy with all-trans-retinoic acid and arsenic trioxide in pediatric acute promyelocytic leukemia
10.3389/fped.2025.1742083 · 2025 · External reference
Predictors of early death, serious hemorrhage, and differentiation syndrome in Japanese patients with acute promyelocytic leukemia
10.1007/s00277-020-04245-6 · ExternalCitation · doi-reference
Early predictor for differentiation syndrome in newly diagnosed acute promyelocytic leukaemia patients treated with single-agent arsenic trioxide
10.1007/s00277-024-05776-y · ExternalCitation · doi-reference
Thromboembolism in adult patients with acute promyelocytic leukemia: Clinical characteristics, risk factors, and a predictive nomogram
10.1007/s00277-025-06251-y · ExternalCitation · doi-reference
Efficacy and safety analysis of different treatment regimens in newly diagnosed acute promyelocytic leukemia
10.1007/s00277-025-06495-8 · ExternalCitation · doi-reference
Does differentiation syndrome in newly diagnosed acute promyelocytic leukemia warrant systemic antifungal therapy? A real-world clinical study
10.1007/s00277-026-06729-3 · ExternalCitation · doi-reference
Understanding the differentiation syndrome in acute promyelocytic leukemia: A comprehensive updated review
10.1007/s10637-025-01556-1 · ExternalCitation · doi-reference
The kinetics of white blood cell and the predictive factors of leukocytosis under oral or intravenous arsenic as the first-line treatment for acute promyelocytic leukemia
10.1016/j.leukres.2017.09.006 · ExternalCitation · doi-reference
Distinctive features associated with differentiation syndrome in acute promyelocytic leukemia in patients treated by all-trans retinoic acid and arsenic trioxide
10.1016/j.leukres.2024.107567 · ExternalCitation · doi-reference
The expression of Slit2 and Robo1 increased during retinoic acid syndrome in acute promyelocytic leukemia and impacted differentiated cell migration
10.1016/j.tranon.2022.101370 · ExternalCitation · doi-reference
Improved prevention and treatment strategies for differentiation syndrome contribute to reducing early mortality in patients with acute promyelocytic leukemia
10.1038/s41408-024-01074-y · ExternalCitation · doi-reference
Anti-inflammatory 25(Oh)D(3), a natural steroid hormone, may complement all-trans retinoic acid therapy for differentiation syndrome in acute promyelocytic leukemia
10.1038/s41419-025-08109-7 · ExternalCitation · doi-reference
Influence of body mass index on incidence and prognosis of acute myeloid leukemia and acute promyelocytic leukemia: A meta-analysis
10.1038/s41598-017-18278-x · ExternalCitation · doi-reference
Progressive hyperleukocytosis is a relevant predictive marker for differentiation syndrome, early death, and subsequent relapse in acute promyelocytic leukemia
10.1038/s41598-019-47937-4 · ExternalCitation · doi-reference
Differentiation therapy for acute promyelocytic leukemia
10.1056/nejm199710093371509 · ExternalCitation · doi-reference
Differentiation syndrome in acute promyelocytic leukaemia
10.1111/bjh.16151 · ExternalCitation · doi-reference
Leucocytosis during induction therapy with all-trans-retinoic acid and arsenic trioxide in acute promyelocytic leukaemia predicts differentiation syndrome and treatment-related complications
10.1111/bjh.19759 · ExternalCitation · doi-reference
Advances in understanding the pulmonary infiltration in acute promyelocytic leukaemia
10.1111/j.1365-2141.2010.08325.x · ExternalCitation · doi-reference
Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: A multicenter study by the Pethema Group
10.1182/blood-2003-07-2462 · ExternalCitation · doi-reference
Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: Characteristics, outcome, and prognostic factors
10.1182/blood-2008-07-168617 · ExternalCitation · doi-reference
Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: Triggering the differentiation syndrome
10.1182/blood-2009-02-204834 · ExternalCitation · doi-reference
Increased Bmi correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the Aida protocols
10.1182/blood-2011-07-369595 · ExternalCitation · doi-reference
Acute promyelocytic leukemia: Progress far and wide
10.1182/blood-2012-12-470757 · ExternalCitation · doi-reference
Management of acute promyelocytic leukemia: Updated recommendations from an expert panel of the European Leukemianet
10.1182/blood-2019-01-894980 · ExternalCitation · doi-reference
Acute promyelocytic leukemia: Long-term outcomes from the Harmony Project
10.1182/blood.2024026186 · ExternalCitation · doi-reference
Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European Apl Group
10.1182/blood.v92.8.2712 · ExternalCitation · doi-reference
Characteristics and predictors of early hospital deaths in newly diagnosed Apl: A 13-year population-wide study
10.1182/bloodadvances.2021004789 · ExternalCitation · doi-reference
Early mortality in patients with acute promyelocytic leukemia: A systematic review and meta-analysis
10.1186/s13054-025-05743-7 · ExternalCitation · doi-reference
Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide
10.1200/jco.2000.18.13.2620 · ExternalCitation · doi-reference
Influence of white blood cell count trajectories on the risk of differentiation syndrome during induction therapy with all-trans-retinoic acid and arsenic trioxide in pediatric acute promyelocytic leukemia
10.3389/fped.2025.1742083 · ExternalCitation · doi-reference
Differentiation syndrome in acute leukemia: Apl and beyond
10.3390/cancers15194767 · ExternalCitation · doi-reference
Differentiation syndrome in acute myeloid leukemia: Molecular mechanisms, clinical spectrum, and emerging therapeutic paradigms
10.3390/ijms27041775 · ExternalCitation · doi-reference
Dynamic changes and multiplication rate of white blood cell count may direct the timing of cytoreduction chemotherapy during induction treatment in newly diagnosed acute promyelocytic leukemia with low-intermediate risk
10.3892/mco.2021.2274 · ExternalCitation · doi-reference
The "retinoic acid syndrome" in acute promyelocytic leukemia
10.7326/0003-4819-117-4-292 · ExternalCitation · doi-reference
